All In Biotech

Drug Trial Radar · NCT01805856

Antimicrobial Prophylaxis in Thyroid and Parathyroid Surgery

Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Thyroid and Parathyroid Surgery

Last checked: Nov 20, 2026Latest source record: Mar 6, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 2,164 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,164

Actual

Start

Nov 2010

Primary completion

May 2012

Study completion May 2012

Sponsor

Lead sponsor
Ito HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 6, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 10 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The effectiveness of antimicrobial prophylaxis (AMP) for prevention of surgical site infection (SSI) following thyroid and parathyroid surgery remains uncertain. Present prospective randomized control study (Ito-RCT1) assessed the effectiveness of AMP in clean neck surgery associated with thyroid and parathyroid disease.

Conditions

  • Thyroid Disease
  • Parathyroid Disease

Interventions

  • PIPC piperacillin sodiumDrug

  • CEZ, cefazolin sodiumDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Surgical site infections after thyroid and parathyroid surgeryTime frame: 1 month after operation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ito Hospital

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.